Nuvation Bio scores first FDA approval for new lung cancer drug

Nuvation Bio on Wednesday won FDA approval with its first commercialized drug, Ibtrozi, for advanced ROS1-positive non-small cell lung cancer (NSCLC). The approval of Ibtrozi, known generically as taletrectinib, follows the company's purchase of AnHeart ...